Download presentation
Presentation is loading. Please wait.
1
Fig. 1 Kaplan–Meier curves of post-progression survival (PPS) in the docetaxel and best supportive care (BSC) groups. Median PPS was 5.4 months in the docetaxel group and 3.3 months in the BSC group (P = 0.005). (—) docetaxel group; (---) BSC group. From: Survival analysis of platinum-refractory patients with advanced esophageal cancer treated with docetaxel or best supportive care alone: a retrospective study Dis Esophagus. 2014;27(8): doi: /dote.12246 Dis Esophagus | © 2014 Wiley Periodicals, Inc. and the International Society for Diseases of the Esophagus
2
Fig. 2 Hazard ratios for post-progression survival with different combination of covariates between the docetaxel and best supportive care (BSC) groups. CI, confidence interval. From: Survival analysis of platinum-refractory patients with advanced esophageal cancer treated with docetaxel or best supportive care alone: a retrospective study Dis Esophagus. 2014;27(8): doi: /dote.12246 Dis Esophagus | © 2014 Wiley Periodicals, Inc. and the International Society for Diseases of the Esophagus
3
Fig. 3 Kaplan–Meier curves of post-progression survival (PPS) according to Glasgow prognostic score (GPS). (a) Median PPSs were 7.1 months (95% confidence interval [CI] 4.4–9.7) in patients with GPS 0, 4.9 months (95% CI 4.3–5.6) with GPS 1, and 2.7 months (95% CI 1.6–3.8) with GPS 2. There were significant differences between the docetaxel and best supportive care (BSC) groups in patients with GPS scores of (b) 0 and (c) 1, but not (d) GPS 2. (a) (—) GPS 0; (---) GPS 1; (-–) GPS 2. (b) GPS 0: (—) docetaxel group; (---) BSC group. Hazard ratio 0.39 (95% CI 0.18–0.86); P = (c) GPS 1: (—) docetaxel group; (---) BSC group. Hazard ratio 0.35 (95% CI 0.17–0.75); P = (d) GPS 2: (—) docetaxel group; (---) BSC group. Hazard ratio 1.03 (95% CI 0.51–2.07); P = 0.95. From: Survival analysis of platinum-refractory patients with advanced esophageal cancer treated with docetaxel or best supportive care alone: a retrospective study Dis Esophagus. 2014;27(8): doi: /dote.12246 Dis Esophagus | © 2014 Wiley Periodicals, Inc. and the International Society for Diseases of the Esophagus
![Fig. 3 Kaplan–Meier curves of post-progression survival (PPS) according to Glasgow prognostic score (GPS). (a) Median PPSs were 7.1 months (95% confidence interval [CI] 4.4–9.7) in patients with GPS 0, 4.9 months (95% CI 4.3–5.6) with GPS 1, and 2.7 months (95% CI 1.6–3.8) with GPS 2. There were significant differences between the docetaxel and best supportive care (BSC) groups in patients with GPS scores of (b) 0 and (c) 1, but not (d) GPS 2. (a) (—) GPS 0; (---) GPS 1; (-–) GPS 2. (b) GPS 0: (—) docetaxel group; (---) BSC group. Hazard ratio 0.39 (95% CI 0.18–0.86); P = (c) GPS 1: (—) docetaxel group; (---) BSC group. Hazard ratio 0.35 (95% CI 0.17–0.75); P = (d) GPS 2: (—) docetaxel group; (---) BSC group. Hazard ratio 1.03 (95% CI 0.51–2.07); P = 0.95.](http://slideplayer.com./slide/13874716/85/images/3/Fig.+3+Kaplan%E2%80%93Meier+curves+of+post-progression+survival+%28PPS%29+according+to+Glasgow+prognostic+score+%28GPS%29.+%28a%29+Median+PPSs+were+7.1+months+%2895%25+confidence+interval+%5BCI%5D+4.4%E2%80%939.7%29+in+patients+with+GPS+0%2C+4.9+months+%2895%25+CI+4.3%E2%80%935.6%29+with+GPS+1%2C+and+2.7+months+%2895%25+CI+1.6%E2%80%933.8%29+with+GPS+2.+There+were+significant+differences+between+the+docetaxel+and+best+supportive+care+%28BSC%29+groups+in+patients+with+GPS+scores+of+%28b%29+0+and+%28c%29+1%2C+but+not+%28d%29+GPS+2.+%28a%29+%28%E2%80%94%29+GPS+0%3B+%28---%29+GPS+1%3B+%28-%E2%80%93%29+GPS+2.+%28b%29+GPS+0%3A+%28%E2%80%94%29+docetaxel+group%3B+%28---%29+BSC+group.+Hazard+ratio+0.39+%2895%25+CI+0.18%E2%80%930.86%29%3B+P+%3D+%28c%29+GPS+1%3A+%28%E2%80%94%29+docetaxel+group%3B+%28---%29+BSC+group.+Hazard+ratio+0.35+%2895%25+CI+0.17%E2%80%930.75%29%3B+P+%3D+%28d%29+GPS+2%3A+%28%E2%80%94%29+docetaxel+group%3B+%28---%29+BSC+group.+Hazard+ratio+1.03+%2895%25+CI+0.51%E2%80%932.07%29%3B+P+%3D+0.95..jpg "From: Survival analysis of platinum-refractory patients with advanced esophageal cancer treated with docetaxel or best supportive care alone: a retrospective study. Dis Esophagus. 2014;27(8): doi: /dote Dis Esophagus | © 2014 Wiley Periodicals, Inc. and the International Society for Diseases of the Esophagus.")
Similar presentations
